Clinical Research Trials
Learn about the latest clinical trials from Memorial Radiation Oncology Medical Group.
Prostate
Prostate Stereotactic Radiotherapy Boost Protocol
Stereotactic body radiotherapy (SBRT) boost to the prostate following conventionally fractionated radiation therapy to the prostate and pelvic lymph nodes is an advanced treatment strategy for prostate cancer. This approach combines the broad coverage of conventional radiotherapy to address both the primary tumor and potential microscopic disease in the pelvic lymph nodes with the precision of SBRT to deliver a high-dose boost directly to the prostate. The SBRT boost enhances local tumor control by intensifying the radiation dose to the prostate while minimizing exposure to surrounding healthy tissues, thereby potentially improving biochemical progression-free survival rates. This combined modality aims to maximize therapeutic efficacy while reducing toxicity, but it requires meticulous planning and patient selection to optimize outcomes and minimize the risk of adverse effects.
LEARN MORE
Head and Neck
Nanoray-312
NANORAY-312 is a global Phase III clinical trial evaluating the efficacy and safety of radiotherapy-activated NBTXR3 nanoparticles in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who are ineligible for chemotherapy. This open-label, randomized study compares the outcomes of patients receiving NBTXR3 with or without cetuximab alongside radiotherapy versus those receiving radiotherapy with or without cetuximab alone. Co-led by Dr. Sue Yom of the University of California, San Francisco, and Dr. Christophe Le Tourneau of Institut Curie in Paris, the trial aims to enroll 500 patients across the United States, Europe, and Asia. The primary endpoint is progression-free survival, with key secondary endpoints including overall survival, response rates, and quality of life measures. NBTXR3 consists of functionalized hafnium oxide nanoparticles designed to enhance the tumor-killing effects of radiotherapy and stimulate an adaptive immune response. The U.S. Food and Drug Administration has granted Fast Track designation to NBTXR3 for this indication, highlighting its potential to address unmet medical needs in this high-risk patient population.
LEARN MORE